Similarly, reslizumab, a humanized IgG4 kappa mAb that binds to human IL-5, showed a reduction in eosinophil infiltrate but little disease remission in a double-blind, placebo-controlled RCT in 226 EoE patients [159]. This evidence concerns the gene IL5 and eosinophilic esophagitis.